Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Jan Ulrich

Ophthalmology Chapel Hill, NC Medical Doctor

NPI 1326224387 CMS profile 1254826

5151 Bioinformatics Building Cb 7040, Unc Department Of Ophthalmology, Chapel Hill, NC 27599

Open in the dashboard

General payments

$597

10 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Jan Ulrich of Chapel Hill, NC is reported in the CMS Open Payments database as having received $597 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 34th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $178 5
2020 General $108 1
2019 General $311 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jan Ulrich
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Jan Ulrich were reported at $0. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Jan Ulrich Ophthalmology median Middle half National median
2019 $311 $258 $104–$655 $163
2020 $108 $126 $45–$321 $114
2021 $178 $205 $76–$534 $132
2022 $0 $266 $100–$678 $149
2023 $0 $308 $117–$745 $160
2024 $0 $340 $127–$846 $164
2025 $0 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Genentech USA, Inc. $253 2 payments
  2. Alcon Vision LLC $111 1 payment
  3. Carl Zeiss Meditec USA, Inc. $100 2 payments
  4. TissueTech, Inc. $44 1 payment
  5. Iridex Corporation $41 1 payment
  6. Dutch Ophthalmic, USA $19 1 payment
  7. Carl Zeiss Meditec, Inc. $15 1 payment
  8. Novartis Pharmaceuticals Corporation $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $597 10 payments
Products named General payments · program years 2019–2021
  1. Lucentis $253 2 payments
  2. ARTEVO 800 $115 3 payments
  3. PROKERA $44 1 payment
  4. AMNIOGRAFT $44 1 payment
  5. EVA Ophthalmic Surgical System $19 1 payment
  6. BEOVU $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

74

Median for Ophthalmology: 891

Drug cost

$2,548

Median for Ophthalmology: $68,233

Branded share of claims

27%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 42 $2,034
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 20 $416
Latanoprost Generic 12 $97

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$803,338

Of which drugs: $602,615

Medicare patients

547

Average age 75

Services billed

10,199

286 women, 261 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 46%
Diabetes 44%
Ischemic heart disease 26%
Chronic kidney disease 26%
Depression 21%
Osteoporosis 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 61 614 $400,858
Injection, faricimab-svoa, 0.1 mg J2777 Office 16 5,340 $146,114
Injection, bevacizumab, 10 mg J9035 Office 81 371 $20,075

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record